This is an excerpt from a 2,920-word article in the March 26, 2018, issue of THE DARK REPORT. The complete article is available for a limited time to all readers, and available at all times to paid members of the Dark Intelligence Group.
CEO SUMMARY: Here’s the first look for the lab industry at an important
CEO SUMMARY: A disruptive force that involves precision medicine, pharmaceutical companies, and venture capital investors is poised to reshape the clinical laboratory industry. Genetic knowledge makes it possible to match cancer drugs to specific mutations. Pharma companies and professional investors recognize that control of diagnostic technologies and companion diagnostic tests enable them to gain better access
CEO SUMMARY: With each passing month, Theranos is looking more like a traditional clinical laboratory company, based on how it is expanding its patient service center network and courier/logistics system into different regions while pursuing managed care contracts with health insurers. Meanwhile, respected laboratory scientists and physicians are using peer-reviewed medical journals to point out that Theranos has yet to publish details about the performance of its diagnostic technology to enable independent validation.
THERE IS NOW A COMPREHENSIVE GUIDE for lab executives and lab managers interested in learning more about ISO 15189:2012, the latest version of the quality management system (QMS) for medical laboratories.
It is a book titled: “A Practical Guide to ISO 15189 in Laboratory Medicine” and was published last fall by a division of the Association
CEO SUMMARY: In the United Kingdom, a window of opportunity has opened for improving the quality assurance activities of pathology and histopathology laboratories. Last week, at the Frontiers in Laboratory Medicine conference, the newly-published “Pathology Quality Assurance Review” was the focus of several keynote sessions. One recommendation is to develop key assurance indicators (KAIs) that
Last week, THE DARK REPORT was in Birmingham, England, to participate in the sixth annual Frontiers in Laboratory Medicine (FiLM) conference. This event is co-produced by the Association of Clinical Biochemistry (ACB) and THE DARK REPORT. It provides an opportunity to learn more about healthcare in the United Kingdom and how clinical laboratories serve this single-payer
CEO SUMMARY: Australia just conducted its first summit meeting on laboratory management and a near sell-out crowd showed up to learn the best and latest. For the Americans in the audience, there were several surprises. First, Australia has a highly-competitive laboratory sector, comparable in many aspects to the private sector here in the United States.
CEO SUMMARY: Siemens has a vision of tight integration of in vitro and in vivo diagnostics with informatics to support a single goal with two themes: enhancing work flow in healthcare. Theme one is that these technologies can support better productivity of clinical, operational and administrative processes. Theme two is the advancement of “knowledge medicine”
CEO SUMMARY: At the fifth annual Frontiers in Laboratory Medicine (FiLM) meeting in Birmingham, England, lab administrators and pathologists from the United Kingdom and the United States gathered to share knowledge about innovations in the management of clinical laboratories. The event sold out for the second consecutive year, demonstrating the keen interest in the United
CEO SUMMARY: To date, only a handful of total laboratory automation (TLA) projects have been implemented in Great Britain. One of those first TLA projects is at the Royal Free Hospital, Hampstead, located in the northern suburbs of London. Design work started in 1998 and the first phase became operational in 2000. Despite Britain’s single-payer